文献速递肿瘤 PET/CT核素与放射性配体治疗

89Zr标记PSMA示踪剂用于前列腺癌患者PET/CT显像

An 89Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients.
PubMed 文献 · J Nucl Med · 2021-07-29

在14例生化复发且常规PSMA示踪剂PET阴性患者中,注射89Zr-PSMA-DFO后6天内显像,8例共检出15个PSMA阳性病灶,其中5例据此接受了病灶靶向放疗。89Zr-PSMA-DFO的对比噪声比和SUVmax均显著高于原PET,提示延长显像时间可能提高弱PSMA阳性病灶检出。

要点

  • 常规PSMA示踪剂PET阴性者中,89Zr-PSMA-DFO使8/14例检出15个病灶。
  • 肾脏受照剂量最高为3.3±0.7 mGy/MBq,有效剂量0.15±0.04 mSv/MBq。

核心结论

  • 对弱PSMA表达患者,现有PSMA示踪剂注射后至显像间隔内配体可能未充分内化,延长至6天内显像的89Zr-PSMA-DFO可提高病灶检出,但需权衡辐射暴露与转移灶定向治疗或挽救放疗的潜在获益。

研究设计与样本

  • 单中心研究,纳入14例生化复发且68Ga-PSMA-11或18F-JK-PSMA-7 PET无PSMA阳性病灶的前列腺癌患者。
  • 阴性扫描后5周内行89Zr-PSMA-DFO PET(117±16 MBq),注射后6天内采集。

主要发现

  • 8/14例检出15个PSMA阳性病灶,表现为局部复发3/8、淋巴结转移3/8、远处病灶2/8。
  • 15个病灶中14个经组织学、放疗后临床随访或后续影像支持其合理性。
  • 原PET上7/15病灶有轻度摄取但对比噪声比过低,89Zr-PSMA-DFO的对比噪声比与SUVmax均显著更高。

关键数值与推荐

  • 对比噪声比:现有示踪剂2.4±3.7,89Zr-PSMA-DFO 10.2±8.5,P=0.0014。
  • SUVmax:原PET 4.7±2.8,89Zr-PSMA-DFO 11.5±5.8,P=0.0001。
  • 肾脏剂量3.3±0.7 mGy/MBq,有效剂量0.15±0.04 mSv/MBq。
  • 基于89Zr-PSMA-DFO PET,5/8例接受病灶靶向放疗,2/8例接受雄激素剥夺治疗,1/8例未治疗。

临床怎么用

  • 对常规PSMA示踪剂PET阴性但临床高度怀疑复发者,可考虑89Zr-PSMA-DFO延迟显像以寻找弱PSMA阳性病灶。
  • 阳性结果可支持转移灶定向治疗或挽救放疗决策,但需结合辐射剂量评估个体获益风险。

局限性

  • 样本量仅14例,为小样本探索性研究,结论需更大规模研究验证。
  • 原文未报告无对照组的诊断效能指标及长期治疗结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The short half-life of existing prostate-specific membrane antigen (PSMA) tracers limits their time for internalization into tumor cells after injection, which is an essential prerequisite for robust detection of tumor lesions with low PSMA expression on PET/CT scans. Because of its longer half-life, the 89Zr-labeled ligand 89Zr-PSMA-DFO allows acquisition of PET scans up to 6 d after injection, thereby overcoming the above limitation. We investigated whether 89Zr-PSMA-DFO allowed more sensitive detection of weak PSMA-positive prostate cancer lesions. Methods: We selected 14 prostate cancer patients with biochemical recurrence who exhibited no PSMA-positive lesions on a PET scan acquired with existing PSMA tracers (68Ga-PSMA-11, 18F-JK-PSMA-7). Within 5 wk after the negative scan result, we obtained a second PSMA PET scan using 89Zr-PSMA-DFO (117 ± 16 MBq, PET acquisition within 6 d of injection). Results:89Zr-PSMA-DFO detected 15 PSMA-positive lesions in 8 of 14 patients, who had a PET-negative reading of their initial PET scans with existing tracers. In these 8 patients, the new scans revealed localized recurrence of disease (3/8), metastases in lymph nodes (3/8), or lesions at distant sites (2/8). On the basis of these results, patients received lesion-targeted radiotherapies (5/8), androgen deprivation therapies (2/8), or no therapy (1/8). The plausibility of 14 of 15 lesions was supported by histology, clinical follow-up after radiotherapy, or subsequent imaging. Furthermore, comparison of the 15 89Zr-PSMA-DFO-positive lesions with their correlates on the original PET scan revealed that established tracers exhibited mild accumulation in 7 of 15 lesions; however, contrast-to-noise ratios were too low for robust detection of these lesions (contrast-to-noise ratios, 2.4 ± 3.7 for established tracers vs. 10.2 ± 8.5 for 89Zr-PSMA-DFO, P = 0.0014). The SUVmax of the 15 89Zr-PSMA-DFO-positive lesions (11.5 ± 5.8) was significantly higher than the SUVmax on the original PET scans (4.7 ± 2.8, P = 0.0001). Kidneys were the most exposed organ, with doses of 3.3 ± 0.7 mGy/MBq. The effective dose was 0.15 ± 0.04 mSv/MBq. Conclusion: In patients with weak PSMA expression, a longer period of time might be needed for ligand internalization than that offered by existing PSMA tracers to make lesions visible on PET/CT scans. Hence, 89Zr-PSMA-DFO might be of significant benefit to patients in whom the search for weak PSMA-positive lesions is challenging. Radiation exposure should be weighed against the potential benefit of metastasis-directed therapy or salvage radiotherapy, which we initiated in 36% (5/14) of our patients based on their 89Zr-PSMA-DFO PET scans.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Dietlein F, Kobe C, Vázquez SM, et al. An 89Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients. J Nucl Med. 2021. PMID: 34326129. doi:10.2967/jnumed.121.262290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。